How to Get Farxiga (Dapagliflozin) in Massachusetts

Who Can Prescribe Farxiga in Massachusetts?

Any Massachusetts-licensed clinician with prescriptive authority can write a dapagliflozin prescription. That includes physicians (MD/DO), nurse practitioners (NPs), and physician assistants (PAs). Massachusetts grants NPs full practice authority after a supervised period, so many NPs in primary care, endocrinology, cardiology, and nephrology clinics prescribe SGLT2 inhibitors independently.

Primary Care vs. Specialist Prescribers

Most Farxiga prescriptions originate from primary care providers managing type 2 diabetes. Cardiologists and nephrologists also prescribe dapagliflozin for heart failure and CKD, respectively. In the DAPA-HF trial (N=4,744), dapagliflozin 10 mg reduced the composite of worsening heart failure or cardiovascular death by 26% compared with placebo (HR 0.74; 95% CI, 0.65 to 0.85; P<0.001) [1]. That trial drove the 2020 FDA label expansion beyond diabetes, meaning your prescriber does not need to be an endocrinologist.

Telehealth Prescribers in Massachusetts

Massachusetts law permits telehealth prescribing of non-controlled medications, and dapagliflozin is not a controlled substance. A clinician licensed in Massachusetts can evaluate you via video, order baseline labs electronically, and transmit the prescription to your preferred pharmacy. Several national telehealth platforms and Massachusetts-based virtual practices now include SGLT2 inhibitors in their formularies. The Massachusetts Board of Registration in Medicine requires that the provider-patient relationship be established through a real-time audio-visual encounter before prescribing [2].

Required Labs Before Starting Farxiga

Dapagliflozin acts on the sodium-glucose cotransporter 2 in the proximal renal tubule, increasing urinary glucose excretion. Before a clinician writes the prescription, they will order a standard set of baseline labs.

Baseline Lab Panel

The FDA-approved prescribing information for Farxiga recommends checking renal function (eGFR), serum potassium, and blood glucose parameters prior to initiation [3]. Typical pre-Farxiga labs include:

• HbA1c (if prescribed for diabetes): establishes glycemic baseline
• eGFR / serum creatinine: Farxiga is not recommended for initiation in patients with eGFR <20 mL/min/1.73 m² for CKD; the threshold differs by indication
• Serum potassium: especially relevant if the patient takes ACE inhibitors, ARBs, or potassium-sparing diuretics
• Urinalysis: screens for active urinary tract infections or genital mycotic infections, which SGLT2 inhibitors can worsen
• Lipid panel and blood pressure: baseline cardiovascular risk assessment

Monitoring After Initiation

The ADA Standards of Care (2025) recommend rechecking eGFR and potassium within 1 to 3 months of SGLT2 inhibitor initiation, then at least annually [4]. A transient eGFR dip of 10 to 30% is expected in the first weeks and is not a reason to discontinue therapy.

Prior Authorization for Farxiga in Massachusetts

Most commercial insurers and MassHealth require prior authorization (PA) before covering brand-name Farxiga. PA is not a denial. It is a documentation step.

What Documents Your Provider Needs

A PA request for Farxiga typically requires:

1. Diagnosis code (ICD-10): E11.x for type 2 diabetes, I50.x for heart failure, N18.x for CKD
2. Recent lab values: HbA1c, eGFR, and for diabetes patients, evidence that metformin was tried first (or a documented contraindication)
3. Clinical rationale: a brief note explaining why dapagliflozin is preferred over formulary alternatives
4. Step therapy documentation: many plans require failure of or intolerance to metformin before approving an SGLT2 inhibitor for diabetes; heart failure and CKD indications may bypass the step therapy requirement

According to MassHealth Drug List updates, dapagliflozin is covered under "prior authorization required" status for type 2 diabetes, heart failure, and CKD indications [5]. Approval turnaround is typically 24 to 72 hours. Emergency or urgent PAs can be processed within 24 hours under Massachusetts Division of Insurance regulations.

If Your PA Is Denied

Massachusetts law (M.G.L. C. 176O, § 13) guarantees the right to an expedited internal appeal and, if that fails, an external review through the state's Office of Patient Protection [6]. Your prescriber can also switch the request to a different covered SGLT2 inhibitor, such as empagliflozin, if your plan covers that without PA. Dr. Robert Gabbay, Chief Scientific and Medical Officer at the American Diabetes Association, has stated: "Access barriers to SGLT2 inhibitors remain a significant concern, as these agents carry benefits that extend well beyond glucose lowering" [7].

Pharmacy Options in Massachusetts

Once you have a valid prescription and insurance approval (or plan to pay out of pocket), several pharmacy pathways exist.

Retail Chain Pharmacies

CVS, Walgreens, and Rite Aid locations across Massachusetts stock brand-name Farxiga. Typical turnaround is same-day to next-day if the medication is in stock and PA is already approved. CVS Health, headquartered in Woonsocket, RI, operates over 400 locations in Massachusetts alone.

Independent and Specialty Pharmacies

Some patients prefer independent pharmacies for more personalized service or because their insurer directs them to a specialty pharmacy for higher-cost brand medications. Specialty pharmacies often handle the PA process on behalf of the provider.

503A Compounding Pharmacies

Massachusetts-licensed 503A compounding pharmacies can prepare dapagliflozin formulations and ship within the state. This route is primarily relevant for patients who need a non-standard dose, cannot swallow tablets, or require a formulation without certain excipients. The Massachusetts Board of Registration in Pharmacy oversees 503A licensure and compliance with USP 795/800 standards [8]. Note that a compounded version is not AB-rated interchangeable with brand Farxiga and may not be covered by insurance.

Mail-Order Pharmacy

Many Massachusetts insurers offer 90-day mail-order supply through their pharmacy benefit manager, which can reduce per-tablet cost and eliminate monthly pharmacy trips.

Cost and Savings Strategies

Farxiga carries a wholesale acquisition cost (WAC) of approximately $596 per 30-day supply at the 10 mg dose. Out-of-pocket cost varies widely depending on insurance.

AstraZeneca Copay Savings Card

Commercially insured patients may be eligible for AstraZeneca's copay assistance program, reducing out-of-pocket costs to as low as $0 per month, with a maximum annual benefit. This card cannot be used with government insurance (Medicare, Medicaid, Tricare) [9].

MassHealth Coverage

MassHealth covers Farxiga with prior authorization. Patients enrolled in MassHealth Standard or CarePlus typically pay $0 to $3.65 per prescription depending on their plan tier [5].

Medicare Part D

Medicare Part D plans vary. Dapagliflozin appears on many Part D formularies at Tier 3 (preferred brand) or Tier 4 (non-preferred brand). Patients in the coverage gap may benefit from AstraZeneca's Medicare patient assistance program. The Inflation Reduction Act's $2,000 annual out-of-pocket cap on Part D spending (effective 2025) also applies to Farxiga [10].

GoodRx and Discount Programs

Uninsured patients can use pharmacy discount cards. GoodRx lists cash prices for Farxiga in the Boston metro area ranging from approximately $480 to $560 for a 30-day supply of 10 mg tablets, though prices fluctuate.

How Long Until You Receive Farxiga in Massachusetts

Timeline depends on three variables: prescription type, PA status, and pharmacy channel.

Best-Case Scenario

If your insurer does not require PA (or PA is already approved) and your retail pharmacy has Farxiga in stock, you can pick it up the same day the e-prescription is transmitted. That is often within hours of your appointment.

Typical Scenario With PA

For most commercially insured or MassHealth patients, expect 2 to 5 business days. The prescriber submits the PA electronically, the insurer adjudicates within 24 to 72 hours, and the pharmacy fills once approved.

Mail-Order or 503A Compounding

Mail-order pharmacies generally deliver within 5 to 7 business days from order placement. 503A compounding may take 3 to 10 business days depending on the pharmacy's queue and shipping method.

Transferring a Farxiga Prescription to Massachusetts

If you are relocating to Massachusetts from another state, your existing Farxiga prescription can be transferred. Massachusetts allows inter-state prescription transfers for non-controlled medications. Call your new pharmacy and provide the details of your current pharmacy; the pharmacist will handle the transfer directly.

If your out-of-state prescriber is not licensed in Massachusetts, you will need a new prescription from a Massachusetts-licensed provider. Telehealth makes this straightforward. Bring your medication history, recent lab results, and the name and dose of your current Farxiga regimen to the visit.

Clinical Evidence Supporting Farxiga Access

Dapagliflozin has one of the broadest evidence bases among SGLT2 inhibitors, spanning three major organ systems.

Heart Failure

The DAPA-HF trial enrolled 4,744 patients with heart failure and reduced ejection fraction (HFrEF). At a median follow-up of 18.2 months, dapagliflozin 10 mg reduced the primary composite endpoint by 26% regardless of diabetes status [1]. The subsequent DELIVER trial (N=6,263) extended the benefit to patients with heart failure and preserved ejection fraction (HFpEF), showing a 18% reduction in the composite of cardiovascular death or worsening heart failure (HR 0.82; 95% CI, 0.73 to 0.92) [11].

Chronic Kidney Disease

The DAPA-CKD trial (N=4,304) demonstrated that dapagliflozin reduced the composite of sustained eGFR decline of 50% or more, end-stage kidney disease, or renal/cardiovascular death by 39% (HR 0.61; 95% CI, 0.51 to 0.72; P<0.001) [12]. The trial was stopped early for efficacy. Dr. Hiddo Heerspink, lead investigator, noted: "The magnitude of benefit was consistent across patients with and without type 2 diabetes, supporting SGLT2 inhibitor use as a kidney-protective therapy independent of glycemic status" [12].

Type 2 Diabetes

Dapagliflozin received its original FDA approval in 2014 for glycemic control in type 2 diabetes. Pooled analyses show HbA1c reductions of 0.5% to 0.8% and body weight reductions of 2 to 3 kg over 24 weeks versus placebo [3]. The 2025 ADA Standards of Care recommend SGLT2 inhibitors as preferred second-line agents after metformin for patients with established atherosclerotic cardiovascular disease, heart failure, or CKD [4].

Massachusetts-Specific Telehealth Regulations

Massachusetts expanded telehealth access through Chapter 260 of the Acts of 2020, which made permanent several pandemic-era flexibilities [13]. Key points for Farxiga access:

Audio-Visual Requirement

Prescribers must conduct a synchronous audio-visual evaluation for new patients. Audio-only visits are permitted for follow-up care under certain circumstances, but the initial encounter for a new medication like Farxiga will typically require video.

Insurance Parity

Massachusetts requires commercial insurers to cover telehealth services at the same reimbursement rate as in-person visits (M.G.L. C. 175, § 47BB) [13]. This means your telehealth visit to obtain Farxiga should not cost more than an office visit.

Cross-State Licensing

The prescriber must hold an active Massachusetts medical license. Providers licensed only in other states cannot prescribe to Massachusetts residents through telehealth, even if they are part of a national platform.